A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia
| Autor: | Qingchun Zeng, Bing-Sheng Li, Bin-Tao Huang, Wei-Hong Zhao, Rui-lin Chen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Acute promyelocytic leukemia
Male Cancer Research medicine.medical_specialty Tretinoin Gastroenterology Polymerase Chain Reaction Arsenicals Disease-Free Survival chemistry.chemical_compound Arsenic Trioxide Leukemia Promyelocytic Acute Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Platelet Prospective Studies Arsenic trioxide Aged Aged 80 and over Hematology business.industry Daunorubicin Cytarabine Oxides General Medicine medicine.disease Surgery Survival Rate Leukemia Regimen Midac Oncology chemistry Female business Cytosine |
| Zdroj: | Medical oncology (Northwood, London, England). 31(10) |
| ISSN: | 1559-131X |
| Popis: | This open-label, prospective, observational study aimed to evaluate disease-free survival (DFS), overall survival (OS), PML–RARα polymerase chain reaction (PCR) monitoring and safety in elderly patients with de novo acute promyelocytic leukemia (APL) who were treated with either arsenic trioxide (As2O3) or medium-dose cytosine arabinoside (MiDAC) as frontline consolidation regimens. A total of 167 patients (age ≥65 years old) received all-trans retinoic acid + daunorubicin as induction therapy. Of these patients, 22 died before attaining complete remission; the remaining 145 subjects received MiDAC- or As2O3-based consolidation therapy. As2O3 was superior to MiDAC for improving DFS and OS. This benefit appeared to result from the longer 5-year DFS (92.0 vs. 69.1 %, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink